Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Elahe Taki, Faezeh Soleimani, Arezoo Asadi, Hossein Ghahramanpour, Ali Namvar & Mohsen Heidary. (2022) Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV. Expert Review of Anti-infective Therapy 20:8, pages 1135-1147.
Read now
Read now
Diana Canetti & Vincenzo Spagnuolo. (2021) An evaluation of cabotegravir for HIV treatment and prevention. Expert Opinion on Pharmacotherapy 22:4, pages 403-414.
Read now
Read now
Jenna L. Yager & Peter L. Anderson. (2020) Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy. Expert Opinion on Drug Metabolism & Toxicology 16:6, pages 463-474.
Read now
Read now
David Rial-Crestelo, Adriana Pinto-Martínez & Federico Pulido. (2020) Cabotegravir and rilpivirine for the treatment of HIV. Expert Review of Anti-infective Therapy 18:5, pages 393-404.
Read now
Read now
Cristina Fernandez & Clare L van Halsema. (2019) Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential. HIV/AIDS - Research and Palliative Care 11, pages 179-192.
Read now
Read now
Maria del Mar Gutierrez, Mª Gracia Mateo, Noemí Corbacho, Francesc Vidal & Pere Domingo. (2019) Drug-drug interactions when treating HIV-related metabolic disorders. Expert Opinion on Drug Metabolism & Toxicology 15:10, pages 787-802.
Read now
Read now
Tristan D. McPherson, Magdalena E. Sobieszczyk & Martin Markowitz. (2018) Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1. Expert Opinion on Investigational Drugs 27:4, pages 413-420.
Read now
Read now
Yingshan Han, Thibault Mesplède & Mark A. Wainberg. (2017) Investigational HIV integrase inhibitors in phase I and phase II clinical trials. Expert Opinion on Investigational Drugs 26:11, pages 1207-1213.
Read now
Read now
Thomas Whitfield, Adele Torkington & Clare van Halsema. (2016) Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date. HIV/AIDS - Research and Palliative Care 8, pages 157-164.
Read now
Read now
Articles from other publishers (24)
Yajie Guo, Jingyu Hou, Hao Wu, Ying Chen, Guangnan Liu, Dan Wang, Huili Wang, Longfei Mao, Sanqiang Li & Tong Wang. (2024) Synthesis and discovery of novel 1,2,3-triazole based cabotegravir derivatives with potent anticancer activity. Journal of Molecular Structure 1298, pages 137042.
Crossref
Crossref
Pedro Amariles, Mónica Rivera-Cadavid & Mauricio Ceballos. (2023) Clinical Relevance of Drug Interactions in People Living with Human Immunodeficiency Virus on Antiretroviral Therapy—Update 2022: Systematic Review. Pharmaceutics 15:10, pages 2488.
Crossref
Crossref
Daniela Zizioli, Isabella Zanella, Luca Mignani, Melania Degli Antoni, Francesco Castelli & Eugenia Quiros-Roldan. (2023) Cabotegravir Exposure of Zebrafish (Danio rerio) Embryos Impacts on Neurodevelopment and Behavior. International Journal of Molecular Sciences 24:3, pages 1994.
Crossref
Crossref
Pablo Torres-Vergara, Robin Rivera, Carlos Escudero & Jeffrey Penny. 2023. Advances in Maternal-Fetal Biomedicine. Advances in Maternal-Fetal Biomedicine
149
177
.
Alexa Vyain Zhao, Rustin D. Crutchley, Rakesh Chowdary Guduru, Kathy Ton, Tammie Lam & Amy Cheng Min. (2022) A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection. Retrovirology 19:1.
Crossref
Crossref
Paul Thoueille, Eva Choong, Matthias Cavassini, Thierry Buclin & Laurent A. Decosterd. (2022) Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. Journal of Antimicrobial Chemotherapy 77:2, pages 290-302.
Crossref
Crossref
Nagsen Gautam, JoEllyn M. McMillan, Devendra Kumar, Aditya N. Bade, Qiaoyu Pan, Tanmay A. Kulkarni, Wenkuan Li, Brady Sillman, Nathan A. Smith, Bhagya L. Dyavar Shetty, Adam Szlachetka, Benson J. Edagwa, Howard E. Gendelman & Yazen Alnouti. (2021) Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir. Nature Communications 12:1.
Crossref
Crossref
Daryl Hodge, David J. Back, Sara Gibbons, Saye H. Khoo & Catia Marzolini. (2021) Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine. Clinical Pharmacokinetics 60:7, pages 835-853.
Crossref
Crossref
Aikaterini Zafeiri, Rod T Mitchell, David C Hay & Paul A Fowler. (2021) Over-the-counter analgesics during pregnancy: a comprehensive review of global prevalence and offspring safety. Human Reproduction Update 27:1, pages 67-95.
Crossref
Crossref
Cheríe S. BlairSue LiGordon ChauLeslie CottlePaul RichardsonMark A. MarzinkeSusan H. EshlemanAdeola AdeyeyeAlex R. Rinehart, David Margolis, Marybeth McCauleyCraig W. HendrixRaphael J. Landovitz. (2020) Brief Report: Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077. JAIDS Journal of Acquired Immune Deficiency Syndromes 85:1, pages 93-97.
Crossref
Crossref
Parul Patel, Zhengyu Xue, Karen S King, Laura Parham, Susan Ford, Yu Lou, Kalpana K Bakshi, Kenneth Sutton, David Margolis, Arlene R Hughes & William R Spreen. (2020) Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir. Journal of Antimicrobial Chemotherapy.
Crossref
Crossref
Scott L Letendre, Anthony Mills, Debbie Hagins, Susan Swindells, Franco Felizarta, Jerome Devente, Christopher Bettacchi, Yu Lou, Susan Ford, Kenneth Sutton, Jafar Sadik Shaik, Herta Crauwels, Ronald D’Amico & Parul Patel. (2020) Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults. Journal of Antimicrobial Chemotherapy 75:3, pages 648-655.
Crossref
Crossref
Meredith E. Clement, Ryan Kofron & Raphael J. Landovitz. (2020) Long-acting injectable cabotegravir for the prevention of HIV infection. Current Opinion in HIV and AIDS 15:1, pages 19-26.
Crossref
Crossref
Peter Yaro, Jing Nie, Mingcheng Xu, Kui Zeng, Houhong He, Jianbiao Yao, Ruwei Wang & Su Zeng. (2019) Influence of organic anion transporter 1/3 on the pharmacokinetics and renal excretion of ginkgolides and bilobalide. Journal of Ethnopharmacology 243, pages 112098.
Crossref
Crossref
Brandon Dionne. (2019) Key Principles of Antiretroviral Pharmacology. Infectious Disease Clinics of North America 33:3, pages 787-805.
Crossref
Crossref
Dario Cattaneo & Cristina Gervasoni. (2018) Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor. European Journal of Drug Metabolism and Pharmacokinetics 44:3, pages 319-327.
Crossref
Crossref
Aaron S. Devanathan, Daijha J.C. Anderson, Mackenzie L. Cottrell, Erin M. Burgunder, Ashley C. Saunders & Angela D.M. Kashuba. (2019)
Contemporary Drug–Drug Interactions in
HIV
Treatment
. Clinical Pharmacology & Therapeutics 105:6, pages 1362-1377.
Crossref
Crossref
Ruben van der Galiën, Rob ter Heine, Rick Greupink, Stein J. Schalkwijk, Antonius E. van Herwaarden, Angela Colbers & David M. Burger. (2018) Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps. Clinical Pharmacokinetics 58:3, pages 309-323.
Crossref
Crossref
Melanie R. Nicol, Joseph A. Corbino & Mackenzie L. Cottrell. (2018) Pharmacology of Antiretrovirals in the Female Genital Tract for HIV Prevention. The Journal of Clinical Pharmacology 58:11, pages 1381-1395.
Crossref
Crossref
Hans-Jürgen Stellbrink & Christian Hoffmann. (2018) Cabotegravir. Current Opinion in HIV and AIDS 13:4, pages 334-340.
Crossref
Crossref
Elisa Lozano, Oscar Briz, Rocio Macias, Maria Serrano, Jose Marin & Elisa Herraez. (2018) Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition. Journal of Personalized Medicine 8:2, pages 14.
Crossref
Crossref
Anton Ivanyuk, Françoise Livio, Jérôme Biollaz & Thierry Buclin. (2017) Renal Drug Transporters and Drug Interactions. Clinical Pharmacokinetics 56:8, pages 825-892.
Crossref
Crossref
Christine Trezza, Susan L. Ford, Elizabeth Gould, Yu Lou, Chuyun Huang, James M. Ritter, Ann M. Buchanan, William Spreen & Parul Patel. (2017) Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women. British Journal of Clinical Pharmacology 83:7, pages 1499-1505.
Crossref
Crossref
Harma Ellens, Marta Johnson, Sarah K. Lawrence, Cory Watson, Liangfu Chen & Lauren E. Richards-Peterson. (2017) Prediction of the Transporter-Mediated Drug-Drug Interaction Potential of Dabrafenib and Its Major Circulating Metabolites. Drug Metabolism and Disposition 45:6, pages 646-656.
Crossref
Crossref